D. E. Shaw & Co. Inc. Has $366,000 Position in Generation Bio Co. (NASDAQ:GBIO)

D. E. Shaw & Co. Inc. lowered its stake in shares of Generation Bio Co. (NASDAQ:GBIO) by 29.3% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 344,922 shares of the company’s stock after selling 143,227 shares during the period. D. E. Shaw & Co. Inc. owned about 0.52% of Generation Bio worth $366,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. Renaissance Technologies LLC boosted its stake in shares of Generation Bio by 62.0% during the 4th quarter. Renaissance Technologies LLC now owns 962,959 shares of the company’s stock valued at $1,021,000 after buying an additional 368,659 shares during the period. Integrated Wealth Concepts LLC acquired a new stake in shares of Generation Bio in the 4th quarter valued at $77,000. JPMorgan Chase & Co. lifted its stake in shares of Generation Bio by 74.9% in the 4th quarter. JPMorgan Chase & Co. now owns 297,705 shares of the company’s stock valued at $316,000 after purchasing an additional 127,513 shares during the last quarter. Finally, Intech Investment Management LLC acquired a new stake in shares of Generation Bio in the 4th quarter valued at $25,000. Institutional investors and hedge funds own 95.22% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts recently issued reports on GBIO shares. Wedbush reaffirmed an “outperform” rating and issued a $5.00 price objective on shares of Generation Bio in a research note on Friday, March 14th. Needham & Company LLC reaffirmed a “buy” rating and issued a $8.00 price objective on shares of Generation Bio in a research note on Thursday, May 8th. Finally, Canaccord Genuity Group reaffirmed a “buy” rating and issued a $9.00 price objective on shares of Generation Bio in a research note on Monday, March 17th.

Generation Bio Trading Down 2.6%

GBIO stock opened at $0.37 on Tuesday. The firm has a market cap of $24.81 million, a PE ratio of -0.17 and a beta of 2.76. Generation Bio Co. has a 1 year low of $0.32 and a 1 year high of $3.65. The company has a fifty day simple moving average of $0.40 and a 200 day simple moving average of $0.78.

Generation Bio (NASDAQ:GBIO) last announced its earnings results on Wednesday, May 7th. The company reported ($0.22) EPS for the quarter, topping the consensus estimate of ($0.25) by $0.03. The firm had revenue of $8.72 million for the quarter, compared to the consensus estimate of $1.70 million. Generation Bio had a negative net margin of 782.86% and a negative return on equity of 104.85%. As a group, analysts forecast that Generation Bio Co. will post -1.75 EPS for the current fiscal year.

Generation Bio Company Profile

Generation Bio Co develops non-viral genetic medicines for the treatment of rare and prevalent diseases. The company develops cell-targeted lipid nanoparticle (ctLNP) platform, a modular delivery system for nucleic acids to avoid off-target clearance by the liver and spleen that enables ctLNPs to persist in systemic circulation, which allows for highly selective and potent ligand-driven targeting to specific tissues and cell types; and novel immune-quiet DNA (iqDNA) to enable long-lasting high levels of gene expression from non-integrating episomes and avoids innate immune sensors that have long prevented DNA from use in non-viral systems.